Bimatoprost 0.03% for the treatment of eyelash hypotrichosis: A pooled safety analysis of six randomized, double-masked clinical trials - 09/05/15
David Pariser, MD, Eastern Virginia Medical School and Virginia Clinical Research, Inc, Norfolk, VA, United States; David Wirta, MD, David Wirta and Associates, Newport Beach, CA, United States; Steven Yoelin, MD, Medical Associates Inc, Newport Beach, CA, United States; Seiji Arase, MD, Health Insurance Naruto Hospital, Tokushima, Japan; Amy McMichael, MD, Wake Forest Baptist Health, Winston-Salem, NC, United States; Emily Weng, MBA, Allergan, Inc, Irvine, CA, United States; Cheri Mao, MS, Allergan, Inc, Irvine, CA, United States; George Demos, Allergan, Inc, Irvine, CA, United States; Amanda VanDenburgh, PhD, MBA, Allergan, Inc, Irvine, CA, United States
Le texte complet de cet article est disponible en PDF. Sponsored by Allergan, Inc, Irvine, CA. Writing and editorial assistance was provided to the authors by Peloton Advantage, Parsippany, NJ, USA and was funded by Allergan, Inc. All authors met the ICMJE authorship criteria. |
Vol 72 - N° 5S1
P. AB14 - mai 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?